A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin by Gerges Geagea, Alice et al.
HAL Id: hal-02389023
https://hal.archives-ouvertes.fr/hal-02389023
Submitted on 2 Dec 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
A novel therapeutic approach to colorectal cancer in
diabetes: role of metformin and rapamycin
Alice Gerges Geagea, Manfredi Rizzo, Abdo Jurjus, Francesco Cappello,
Angelo Leone, Giovanni Tomasello, Céline Gracia, Sahar Al Kattar, Liliane
Massaad-Massade, Assaad Eid
To cite this version:
Alice Gerges Geagea, Manfredi Rizzo, Abdo Jurjus, Francesco Cappello, Angelo Leone, et al.. A novel
therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin. Oncotarget,
Impact journals, 2019. ￿hal-02389023￿
Oncotarget1284www.oncotarget.com
A novel therapeutic approach to colorectal cancer in diabetes: 
role of metformin and rapamycin
Alice Gerges Geagea1,2, Manfredi Rizzo1, Abdo Jurjus2, Francesco Cappello4, Angelo 
Leone4, Giovanni Tomasello4, Céline Gracia3, Sahar Al Kattar2, Liliane Massaad-
Massade3 and Assaad Eid2
1Department of Internal Medicine, University of Palermo, Palermo, Italy
2Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, 
Lebanon
3Equipe Nouvelles Thérapies Anticancéreuses, UMR8203 CNRS, Gustave Roussy, Villejuif, France
4Department of Biomedicine, Neurosciences and Advanced Diagnosis, School Of Medicine of Palermo, Palermo, Italy
Correspondence to: Abdo Jurjus, email: aj00@aub.edu.lb
Assaad Eid, email: ae49@aub.edu.lb
Keywords: colorectal cancer; diabetes mellitus; probiotics; inflammatory cytokines; mTOR
Received: October 30, 2018     Accepted: January 14, 2019     Published: February 12, 2019
Copyright: Gerges Geagea et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 
License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author 
and source are credited.
ABSTRACT
The link between colorectal cancer (CRC), diabetes mellitus (DM) and 
inflammation is well established, and polytherapy, including rapamycin, has been 
adopted. This study is a novel approach that aimed at assessing the effect of a 
combination therapy of metformin and rapamycin on the control or prevention of 
CRC in diabetic animals, in presence or absence of probiotics.
Fifty NOD/SCIDs male mice developed xenograft by inoculating HCT116 
cells. They were equally divided into diabetics (induced by Streptozotocin) and 
non-diabetics. Metformin was given in drinking water, whereas rapamycin was 
administered via intra-peritoneal injections. Probiotics were added to the double 
therapy two weeks before the sacrifice. Assessment was performed by clinical 
observation, histological analysis, Reactive oxygen species (ROS) activities and 
molecular analysis of Interleukin 3 and 6, Tumor Necrosis Factor alpha, AMP-activated 
protein Kinase and the mammalian target of rapamycin. Decreases in the level of 
tumorigenesis resulted, to various extents, with the different treatment regimens. 
The combination of rapamycin and metformin had no significant result, however, after 
adding probiotics to the combination, there was a marked delay in tumor formation 
and reduction of its size, suppression of ROS and a decrease in inflammatory cytokines 
as well as an inhibition of phosphorylated mTOR.
Existing evidence clearly supports the use of rapamycin and metformin especially 
in the presence of probiotics. It also highlighted the possible mechanism of action of the 
2 drugs through AMPK and mTOR signaling pathways and offered preliminary data on 
the significant role of probiotics in the combination. Further investigation to clarify the 
exact role of probiotics and decipher in more details the involved pathways is needed.
INTRODUCTION
Several investigators, including our team, reported 
the co-occurrence of diabetes mellitus (DM) and 
colorectal cancer (CRC) along with bowel inflammation 
and dismicrobism [1–6]. Moreover, multiple reports 
suggested the involvement of the gut microbiome in the 
evolution of DM, and that potential modulation of the 
www.oncotarget.com                                             Oncotarget, 2019, Vol. 10, (No. 13), pp: 1284-1305
           Research Paper
Oncotarget1285www.oncotarget.com
intestinal microbiota could prevent or delay its progression 
[7]. Furthermore, data are increasing about the greater risk 
for CRC in patients with DM by almost 1.2% to 1.5% 
[8]. According to the Global Burden of Disease study 
data, mortality from CRC increased annually from 1990 
through 2013 in line with a worldwide decrease in the age 
of onset of DM [9]. In addition, Type 2 diabetes mellitus 
(T2DM) has been reported to increase the risks of a 
wide spectrum of cancers including CRC, and that 14% 
of CRC patients have T2DM as a comorbid condition at 
diagnosis [10]. They conferred an increased risk of CRC 
in T2DM patients and a higher mortality rate [6, 9, 11–14]. 
In addition, CRC, colorectal adenoma and chronic colitis 
are positively associated with inflammation, T2DM and 
hyperinsulinemia, thus representing the link between 
the various disease entities [15]. Further studies have 
also shown that in human epithelial colorectal cancer 
cells, high glucose or insulin activates a cascade of cross 
reacting pathways leading to an alteration in a panoply 
of proteins in the signaling cascade involved in cell 
proliferation, survival and apoptosis [15].
Moreover, it is also well documented that in diabetes 
and CRC, there is an increased generation of Reactive 
Oxygen Species (ROS). More importantly, in tumors, RO 
metabolites can act as signaling molecules to promote 
cell survival over apoptosis. On the other hand, studies 
have also shown that in diabetes, there is an increased 
production of 20-hydroxyeicosatetraenoic acid (20-
HETE) resulting from arachidonic acid cytochrome P450-
dependent metabolism. 20 HETE contributes, through a 
ROS dependent pathway, to organ damage and plays a 
role in inflammatory responses, carcinogenesis, cardiac 
functions and vascular hypertrophy among others [16, 17]. 
So we hypothesize that inhibitors of 20-HETE synthesis 
might have anticancer and anti-diabetic activities. 
However, the upstream and downstream signaling 
pathways leading to injury are not yet fully studied and 
defined. The mechanistic pathway can be simplified by 
inactivating AMP-activated protein Kinase (AMPK), 
activating the mammalian target of rapamycin (mTOR) 
signaling pathway, and consequently increasing tumor 
development.
It is also important to note that chronic 
inflammation, as a process, forms a favorable environment 
for such a mechanistic pathway to occur. It involves a 
balance between a huge panel of bioactive molecules, 
pro and anti-inflammatory provided from resident or 
infiltrating inflammatory cells [6]. However, a persistent 
or an inadequately resolved chronic inflammation tilts the 
balance in favor of pro-inflammatory agents, may increase 
the risk of several pathologies such as IBD, CRC and 
T2DM.
In case of co-occurrence of diabetes and cancer, 
inflammation is characterized by an upregulation of 
inflammatory cytokines, mainly IL-6, IL-1 and TNF α, 
as well as TGFβ, NFKB, and ROS among others. These 
molecules are reported to be powerful tumor promoters, 
which create a favorable environment for malignancies, 
genomic instability, oxidative stress and angiogenesis. 
All of these phenomena are key players in linking 
inflammation to carcinogenesis and other systemic 
diseases like diabetes [6].
Pharmacologically modulating the inflammatory 
process might be of value in decreasing, preventing or 
even managing the process underlying these diseases [6].
Metformin, an oral biguanide, discovered almost 
a hundred years ago, is prescribed to over 120 million 
people worldwide for the treatment of conditions 
including T2DM, polycystic ovarian syndrome, and 
gestational diabetes [18]. Over the past decade, multiple 
epidemiologic, preclinical and clinical studies have 
consistently associated metformin with decreased cancer 
incidence and cancer-related mortality, shedding light 
on the anti-cancer effects of this hypoglycemic agent [6, 
19]. Although the exact mechanisms of metformin action 
are not entirely understood, there is a robust literature 
that defines the hallmarks of its cellular and molecular 
signaling in colon cancer cell lines with regards to AMPK 
activation that leads to inhibition of mTOR and a reduction 
in translation initiation, thus providing a possible role of 
metformin in the inhibition of cancer cell growth [20, 21].
Similarly, rapamycin, discovered more than 
thirty years ago as an immunosuppressor, has been 
used successfully to reduce organ rejection with kidney 
transplantation [22]. Furthermore, rapamycin inhibited 
cell growth in tumor cell lines including CRC cell lines 
like Caco2, HT29 [23], which involves binding to the 
mammalian target of rapamycin (mTOR) whose signaling 
pathway is critical to cell growth, proliferation, and 
survival; in brief, rapamycin could inhibit most of these 
hallmark processes of cancer [23, 24].
Exploring the possible additive effects of metformin 
(an AMPK activator) and rapamycin (a blocker for 
mTOR activation) might open a new horizon in dealing 
with the two co-morbid disease entities. Furthermore, 
modulation of the microbiota by increasing its diversity 
through probiotic use might hold the promise of effective 
protection against both DM and CRC [25]. The aim of 
this study was to determine the roles of metformin and 
rapamycin, alone and in combination in the management 
of diabetes and colorectal cancer in an ectopic xenografts 
mouse model, at clinical, histological and molecular 
levels, with an emphasis on the downstream signaling 
elicited by these drugs in the presence of probiotics.
RESULTS
Clinical Profile
Mice in group 1 (G1) (controls, non-treated, having 
the HCT116 cells xenograft) had the worst clinical profile. 
Two mice had diarrhea and rectal bleeding as well as 
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weakness and low alertness. In addition, one mouse died 
two weeks before the sacrifice time.
On the other hand, groups treated with metformin, 
with or without rapamycin, had a better clinical profile 
when compared to the mice in G1; however, there were 
no significant changes in stools, and activity. Besides, 
animals treated with probiotics in addition to rapamycin 
and metformin had the best clinical profile, they had no 
diarrhea, and good body conditions. These two groups had 
the lowest DAI as shown in Figure 2. It is also noteworthy 
that there was a trend of decreased body weight in non-
treated G1 mice, but the variations were not significant. 
All mice in the other groups showed a gradual increase in 
body weight without significant differences.
Diabetes induction was successful in all animals 
injected with STZ; they had glycemia levels higher than 
150 mg/dl even 10 days after injection (e.g. 128.52 in 
non-diabetics (ND) G1 and 163.72 in diabetics (D) G5). 
Treatment with metformin was able to reduce glycemia 
levels at all time points, (e.g. G3 and G7 had average 
glycemia levels of 126.6 vs 136.6 mg/dl, respectively).
As expected, rapamycin did not show any glucose 
lowering effect in both ND and D animals (ND- G2 
124.96 vs ND-G1 128.52, p>0.05 and D-G6 175.88 vs 
D-G5 163.72 p>0.05). Moreover, adding a combination of 
metformin and rapamycin did not produce any significant 
added effect in lowering glucose below the metformin 
level alone (e.g. ND-G4A 124.38 vs ND-G3 126.18, 
p>0.05 and D-G8A 146.90 vs D-G7 136.68, p>0.05), 
Figure 1.
Moreover, probiotics added to metformin and 
rapamycin did not exhibit any additive effect in decreasing 
the glucose levels in the sera of animals. In brief, 
metformin alone normalized the glucose levels with no 
added effect from rapamycin and probiotics.
Disease Activity Index (DAI) which included 
multiple parameters was assessed on a regular basis, as 
described before, and a total of none was added for the 
highest disease activity. As expected, the highest indices 
were encountered in the non-treated groups in both D G5 
(6.4) and ND G1 (5.4). However, ND animals treated with 
rapamycin alone G2 (3.6) or metformin alone G3 (4.4) had 
a lower DAI. As for the combination treatment, there was 
a limited additive effect in the ND G4A (2) compared to a 
lack of such an effect in the diabetics G8A (3).
On the other hand, when the combination of 
rapamycin and metformin was supplemented with 
probiotics, the DAI decreased drastically and significantly 
in both ND 4B (0.2) and D G8B (0.8), (Figure 2).
Figure 1: Blood glucose time curve. Note the difference in Glycemia levels between diabetic and non-diabetic groups, as well as 
the drop in glycemia in diabetic animals in groups 7, 8A and 8B treated respectively with metformin alone, metformin and rapamycin, 
probiotics with metformin and rapamycin.
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Tumor frequency and volume
All mice injected with the -HCT116 cells developed 
tumors in their right flank (site of HCT116 injection), 
except for 3 groups; group 4A treated with metformin and 
rapamycin where 4 only out of 5 mice had tumors, and in 
groups 4B and 8B, where probiotics were added, tumor 
formation decreased by 40% as it occurred in only 3 out 
of 5 animals with a significantly smaller size.
Concerning tumor onset, a delay in tumor formation 
was observed in groups treated with metformin and 
rapamycin plus or minus probiotics, when compared to 
non-treated G1 mice. In G1 (non-treated) tumor appeared 
only 7 days after HCT116 injection; In contrast, in G8B 
treated with rapamycin, metformin and probiotics, tumor 
formation was delayed till day 15 by 88% and in 8A till 
day 14, respectively (Table 1), with significantly smaller 
size (Figure 3).
The results showed that the highest tumor volumes 
were obtained in non-treated mice (groups 1 and 5, 1.6 
and 1.45 cm3, respectively). In groups taking rapamycin 
alone or metformin alone, there was a reduction in tumor 
volume of 20% and 35%, respectively (G2 with rapamycin 
1.28 and G3 with metformin 1.04 cm3). For groups taking 
the combined therapy metformin and rapamycin, G4A and 
G8A had also significantly small tumor volumes (G4A 
1.15 and G8A 1.06 cm3) close to volumes from metformin 
alone or rapamycin alone; obviously there was no added 
effect of the 2 drugs. However, groups taking probiotics, 
G4B and G8B, had significantly the lowest tumor volumes 
(1.03 and 0.83 cm3, respectively) at all time points, with 
a decrease in tumor volume of about 36% and 43%, 
respectively (Figures 3 and 4).
Histological alterations
Histological studies performed on the liver and 
kidneys showed no signs of toxicity. On the other hand, 
the histopathology of the xenograft was evaluated. It 
showed a wide range of alterations in the xenograft 
growth and morphology in the various groups. Treatment 
of ND mice with metformin alone, rapamycin alone or 
with the combination plus probiotics, led to various 
degrees of necrosis in the tumor xenograft. The most 
pronounced growth decrease and necrosis were in the 
presence of probiotics. Compared to the non-treated 
mice, those treated had a smaller size tumor, much less 
of inflammatory cells, and a lower density of tumor cells. 
The non-treated showed also some ascites fluid within the 
well circumscribed tumor and less vascularity.
Moreover, in diabetic animals, the same picture 
and trend prevailed with a much lower density of cells 
and more of necrosis in the combination treated mice 
especially with probiotics. However, it is worth noting 
that metformin and rapamycin did not exhibit an additive 
inhibitor effect, yet the density of the tumor cells was 
relatively lower, and the ascites fluid was also less. The 
same findings were consistent in all the animals of a given 
group (Figure 5A–5N).
Descending colon tissues
The microscopic findings in the descending colon 
were scored according to the aforementioned criteria 
by 2 different observers (Figures 6, 7). Concerning the 
descending colon, most of the alterations were recorded 
in groups 1 and 5, not treated controls, non-diabetic and 
diabetic, (Figure 6A-6F), respectively.
Figure 2: Disease activity index (DAI) in the different groups. The values represent mean ± SEM (n = 6). Significance of p<0.05 
was indicated by (*) and (**) when compared to diabetic control and non-diabetic control respectively.
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In group 1, there was a marked hyperplasia with a 
major loss of goblet cells (black circles), polyp formation, 
and inflammatory cells infiltration (black arrows). The 
average score of histopathological changes in G1 was 2.4 
out of 3. Similar but relatively more severe alterations 
were encountered in group 5, the diabetic mice with a 
score of 2.6. Treatment with rapamycin decreased the 
alterations in G2 and G6 with a score of 1.3 in both based 
on the presence of less inflammatory cell aggregates 
(black arrows), less disruption in mucosal architecture and 
irregularities in the epithelial lining as well as submucosal 
edema (star). Similarly, treatment with metformin in 
G3 and G7 improved the alterations seen in G1 and G5 
with more improvement in G3 the non-diabetic (score 
of 0.9) compared to diabetics (score of 1.3). However, 
the inflammatory reaction was more persistent in G1 
(black arrow). On the other hand, the combination (Met+ 
rapamycin) did show more decrease in the morphological 
alterations especially in the non-diabetics G4A (score 0.6) 
compared to G8A (score of 1.0), close to normal with little 
submucosal edema and inflammatory cells.
Concerning the use of probiotics plus the 
combination in G4B and G8B, the tissues of the colon were 
almost normal with scores of 0.1 both in G4B and G8B.
In brief, there was amelioration to various degrees 
in the colonic tissues with more effect in the presence of 
the combination therapy with or without probiotics; on the 
other hand, the histology was close to normal in presence 
of probiotics (Figures 6 and 7).
Mast cells number variations
Concerning mast cells, they are normally present in 
intestinal tissues, they are activated during inflammatory 
reaction; they degranulate and increase in number. One 
of the features of inflammatory bowel diseases is mast 
cell stimulation, secretion and hyperplasia. Hereby, the 
study of the colonic tissues stained with toluidine blue 
showed that the high scores encountered in G1 (12.2) 
and G5 (11.7) decreased. Moreover, the mast cell number 
decreased with the administration of metformin alone and 
rapamycin alone in a significant way when compared to 
controls (p<0.05); G2 (5.8) and G6 (5.6) for rapamycin, 
while G3 (3.4) and G7 (4.2) for metformin. The greatest 
decrease was obtained with the combination of metformin 
and rapamycin with probiotics; G4B (0.9) and G8B 
(0.8) with a significant reduction of 92.6% and 93.2% 
respectively (p<0.05). However, in the diabetic groups 
G4A and G8A, there were no additive effects of metformin 
and rapamycin 3.4 and 4.2, respectively (Figure 9).
Reactive oxygen species changes
Besides, the inhibition of reactive oxygen species 
(ROS) was significant. In general, cancer cells increase 
their rate of ROS production compared with normal cells. 
In this experiment, ROS were assessed in all the colonic 
samples of the various groups using the DHE staining 
technique.
In non-diabetics: groups 2, 3, 4A and 4B, the 
different treatments were able to reduce ROS production 
in a significant manner when compared to controls in G1 
(P = <0.001). In addition, a similar pattern was noted in 
diabetics: groups 6, 7, 8A and 8B compared to control G5 
ROS reduction was significant (p< 0.05). In both G1 and 
G5, the ROS values were similar and relatively very high 
(7268 units), regardless of the diabetic or non-diabetic 
status of the mice.
Actually, in non-diabetics, rapamycin decreased 
significantly ROS production from 7268 in G1 till 
1923 in G2, and a similar trend but to a lesser and also 
Table 1: Frequency and date of tumor formation
Group Treatment Tumors appeared after Number of animals
1 Non Diabetic Non-treated 7 days 5 out of 5
2 Non Diabetic rapamycin 9 days 5 out of 5
3 Non Diabetic Met 9 days 5 out of 5
4A Non Diabetic Met+ rapamycin 14 days 4 out of 5
4B Non Diabetic Met + rapamycin + probiotics 14 days 3 out of 5
5 Diabetic Non-treated 9 days 5 out of 5
6 Diabetic rapamycin 10 days 5 out of 5
7 Diabetic Met 10 days 5 out of 5
8A Diabetic Met + rapamycin 14 days 5 out of 5
8B Diabetic Met + rapamycin + probiotics 15 days 3 out of 5
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significant degree in diabetics (3173 units). As for 
metformin, grossly the effects were similar (G3=1695 
and G7=2150), significantly less than G1 and G5, 
respectively, p<0.05.
On the other hand, there was no additive effect 
for the metformin and rapamycin combination, the 
ROS values were significantly less than the non-treated 
G1 and G5 but relatively more than either metformin 
alone or rapamycin alone (G4A=3533 and G8A=3147). 
Furthermore, the presence of the probiotics in the 
combination therapy made a significant difference in both 
diabetics (G8B=1903) and non-diabetics (G4A=1918). 
In brief, all treatments significantly decreased ROS 
production to various extents; however, the lowest 
values were with metformin and the combination with 
probiotics with the absence of additive effect between 
metformin and rapamycin. All of the differences in the 
mean values of ROS production among the treatment 
groups are greater than would be expected by chance; 
there exist a statistically significant difference (Figures 
10 and 11).
Molecular analysis of relevant genes and 
proteins
Gene Expression of AMPK, mTORC and KI67
Repeatedly, AMPK gene expression was close in 
most non-diabetic groups, close to 1.0 in G1, G2 and 
G3 and decreased by about 31% in G4A (=0.69) and 
39% in group G4B (0.63), with combination therapy or 
combination plus probiotics, respectively.
On the other hand, the non-treated diabetic mice 
in G5 expressed less AMPK by about 31% than the non-
diabetics in G1. In addition, the expression in the rest of 
the diabetics G6, G7 and G8A was not significant. it was 
less then G1 G2 and G3. In diabetics also, a slight increase 
in AMPK was observed when metformin and rapamycin 
were administered alone or in combination. However, 
when probiotics were added to the combination, a decrease 
of about 20% was observed in group 8B compared to 8A, 
similar to non-diabetics with combination G4A and close 
to 4B. It seems that the triple treatment could show a 
distinct difference compared to the other groups (Figure 
12A).
Concerning mTORC expression, it was suppressed 
in all groups except in the rapamycin treated diabetics, 
where the value was highly significant in G6=12.79 
compared to very low expression in all other groups. In 
brief, only rapamycin treatment upregulated mTORC 
(Figure 12B).
As for KI67 genes, whose level of expression 
indicates the proliferation of the cells, the data profile was 
close to the AMPK expression profile. Partial inhibition 
of proliferation was encountered when combination 
treatment was used in non-diabetic with (33%) or without 
(36%) probiotics (Figure 13).
Some decrease of proliferation was encountered 
in all diabetics: 20% in G5, 42% in G6 with rapamycin 
treatment, 30% with metformin treatment in G7, 25.0% 
with rapamycin and metformin G8A and 31% when 
probiotics were added to the combination. Therefore, 
the combination, with or without probiotics decreased 
proliferation by 20-40% (Figure 13).
Gene expression of pro-inflammatory cytokines: IL-3, 
IL-6 and TNFα
As expected the expression of Il-3 genes was 
relatively the highest in the non-treated mice (G1=1 and 
G5=0.9). It was inhibited significantly in non-diabetics by 
rapamycin alone and metformin alone by 89% and 88% 
respectively. Inhibition by the combination therapy plus 
probiotics was by 90%. However, again the combination 
of metformin and rapamycin together inhibited by about 
78% in diabetics; again, there were no added effect but 
rather may be a competitive effect of the 2 drugs. On the 
other hand, in diabetics, the inhibition was very significant 
in all groups (G6=90%) G8A=80%, and G8B=90%, 
However, metformin alone inhibited the expression by 
only 33% compared to G5 which expressed IL-3 by 91% 
(Figure 14A).
Concerning the other interleukin IL-6, its gene 
expression was suppressed in almost all groups to various 
extents except in G1, the non-diabetic, non-treated group 
of mice.
The combination plus probiotics G4B and G8B 
had relatively the highest suppression, 86% and 83%, 
respectively. However, the combination without 
probiotics and rapamycin alone had 84% suppression 
and 76% in non-diabetics. In brief, there was an additive 
effect of both drugs in the diabetics but not in the non-
diabetics (Figure 14B). In the non-treated diabetic 
mice, the expression of IL-6 was low, about 24% with 
rapamycin, 33% with metformin and 45% with the 
combination, and in all the rest of the groups the IL-6 
expression was less, G2=24% G3=33% G4B=45% 
G5=30% G6=17% G8A and G8B=17%. However, 
in non-diabetics, met and rapamycin did not have an 
additive effect but rather a competitive effect G4A=45% 
(Figure 14B).
As for TNFα, its gene expression was extremely 
inhibited >90% in all the non-diabetic groups, and even 
in the non-treated mice both diabetics and no-diabetics. 
However, the TNFα gene expression was relatively 
elevated 4.ww times compared with rapamycin treatment 
and 8.77 times with metformin treatment compared to 
G1 (1.0) and G5 (1.01). There was no additive effect, 
however, in the presence of probiotics G4b and G8B the 
inhibition was almost complete (Figure 14C).
In brief, the administration of metformin alone or 
rapamycin alone induced a decrease in the expression of 
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the inflammatory markers, IL-3, IL-6 and TNF-ɑ in both 
diabetics and non-diabetics. The lowest scores were obtained 
in diabetic and non-diabetic groups taking the triple-therapy 
(metformin, rapamycin and probiotics) when compared to 
non-treated controls. However, a slight increase in IL-3, 
IL-6 and TNF-α was noted when combining rapamycin and 
metformin shedding light on possible alternative signaling 
pathways (Figure 14A, 14B, 14C).
Figure 3: Tumor volumes upon sacrifice. There was no additive effect of the combination therapy. In diabetics, group 8B, the 
probiotics with the combination had a significant antitumor effect. The values represent mean ± SEM (n = 6). Significance of p<0.05 was 
indicated by (*) and (**) when compared to diabetic control and non-diabetic control respectively.
Figure 4: Prototype of tumors upon sacrifice, formed in non-diabetic and diabetic mice treated with rapamycin, 
metformin and their combination with probiotics. Note the difference in tumor size in the different groups; animals from groups 
4B and 8B treated with rapamycin and metformin in combination with probiotics had significantly smaller tumor size when compared to 
groups treated with Met alone, rapamycin alone or untreated animals.
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The three inflammatory markers studied had the 
similar expression profile to a great extent, implicating 
that all treatments produced a prominent decrease in the 
inflammatory response which forms a favorable environment 
for colorectal carcinogenesis development and progress.
Expression of mTOR and p-mTOR at protein level in 
tumors
Data emanating from western blots performed on 
proteins extracted from tumor sections and assessing the 
effect of the different treatments on the expression of 
Figure 5: H&E histological examination of the representative HCT116 xenograft tumors in the different groups. 
(A) a 200x magnification of a tumor section in non-diabetic, injected with HCT116 cells and non-treated showing high cellular density, 
vascularization (black arrows), and tumor cells surrounded by a remarkable infiltration of inflammatory cells (red arrows). (B) a 20x 
magnification showing some necrotic areas in the tumor (Black arrows) in non-diabetics, rapamycin alone (G2) (C) 20x magnification 
showing some necrotic areas in the tumor (Black arrows) in non-diabetics metformin alone (D) 4x and (E) 200x magnification show large 
necrotic areas in the tumor section with low cell density (black arrows) in non-diabetics treated with metformin combined to rapamycin. 
(F) 40x and (G) 200x magnification showing necrotic areas (Black arrows), along with a lower density of the cells in diabetic treated 
with metformin, rapamycin combined with probiotics (G4B). Note that all tumors from 5 animals in the same group showed similar 
morphology. (H) Whole view of a well-demarcated tumor formed with a scanty fibrous capsule and a moderately produced connective 
tissue in diabetic non-treated animals. Note the sheet-like proliferation showing growth of solid tumor cells. (I) 200x magnification of the 
tumor section in G5, note the high density of the cells along with increase in vascularity (black arrows) (J) 200x magnification of a tumor 
section, showing a moderate cells density along with an increase in vascularity (black arrows) in diabetics treated with rapamycin alone 
(G6). (K) 200x magnification of a tumor section, note the moderate density of the cells in diabetics treated with metformin alone (G7). (L) 
200x magnification of tumor section from diabetic mice treated with metformin and rapamycin showing a lesser density of the cells than 
either alone (M) 200x and (N) 20x magnification of tumor section from diabetic mice with the triple therapy showing necrotic areas (Black 
arrows), along with a significant decrease in cellular density.
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Figure 6: High power magnification of H&E stained colonic tissue obtained from the different groups. (A and F) represent 
colon sections from non-treated animals, respectively non-diabetic and diabetic showing a marked hyperplasia with loss of goblet cells 
(black circles), polyp formation (star shape) and inflammatory cells infiltration (black arrows) seen in animals as well as thinning of the 
colonic layers (dotted circle) and extensive crypt dysregulation (star shape). (B and G) animals treated with rapamycin alone in non-
diabetic (G2) and diabetic (G7), respectively show few inflammatory cell aggregates (black arrows), in addition to some dysregulation in 
epithelial cell lining and the sub-mucosal edema (star shape). Colon sections in (C and H) from animals treated with metformin alone, in 
non-diabetics and diabetics, respectively, showing few inflammatory cell aggregates (black arrows) and a close to normal colonic structure. 
(D and I) show normal colonic structure and normal goblet cell distribution, in addition to a moderate and sub-mucosal edema (star shape) 
in non-diabetic and diabetic animals treated with metformin and rapamycin. An almost normal colonic structure is seen in animals treated 
with rapamycin probiotics and metformin as in (E and J).
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mTOR and its phosphorylated form p-mTOR, showed 
different levels of inhibition in the diabetic and non-
diabetic animals (Figure 15).
Data showed that the treatment with rapamycin 
increased the levels of mTOR in both diabetics (G6 
compared to G5) and non-diabetics (G2 compared to G1). 
On the other hand, treatment with metformin introduced 
no change in m-TOR and p-mTOR (G3 versus G1) in non-
diabetics but a significant increase in diabetics (G7 compared 
to G5). Using the combination of metformin and rapamycin, 
did not introduce any significant variations, thus leading us 
to conclude one more time that the 2 drugs do not have an 
additive effect on mTOR. However, by adding probiotics 
to the combination, mTOR expression increased in non-
diabetics (G4B=0.85 compared to G1=0.58) and decreased 
slightly in diabetics, G8B=0.57 compared to G5 0.77).
The p-mTOR decrease was really significant when 
probiotics were added to metformin and rapamycin in 
both non-diabetics and diabetics. In addition, p-mTOR 
was also significantly inhibited with either rapamycin or 
metformin treatment in diabetics (G6=0.37, G7=0.449 vs 
G5=0.61).
In brief, it is important to note that the treatment 
with rapamycin alone or metformin alone was able to 
inhibit mTOR activity via decreasing its phosphorylation. 
However, the effect or rapamycin was more significant. 
The highest inhibition of p-mTOR was obtained when 
adding probiotics to the combination in diabetic and 
non-diabetic mice. In addition, there was no additive 
inhibitory effect of metformin and rapamycin, but the 
opposite is true, a slight increase in p-mTOR was noted 
(Figure 15).
Figure 7: Colonic inflammation average in the different groups. Note the significant drop in inflammation in groups treated with 
metformin, rapamycin and probiotics (group 4B and 8B) where the lowest scores were obtained (0.1). The values represent mean ± SEM 
(n = 6). Significance of p<0.05 was indicated by (*) when compared to diabetic control, and non-diabetic control (**); and (***) indicated 
significance between G8A and 8B.
Figure 8: (A and B) Toluidine Blue stained colonic section (13A) showing a typical mast cell (black arrow) seen in the 
submucosa of an inflamed colon (13B 400X magnification).
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DISCUSSION
Clinical observations and studies indicate that the 
prevalence of diabetes in newly diagnosed cancer patients 
ranges from 8 to 18%, suggesting bidirectional association 
between these 2 diseases [26–28]. In addition, publications 
in the past 5 years have also suggested the link between 
first line hypoglycemic medications like metformin and 
the delay in initiation of cancer [29–31]. However, the 
mechanism is still unclear, despite the fact that metformin 
is capable of activating AMPK involved in tumorigenesis 
[32].
On the other hand, rapamycin, originally used 
as an antifungal agent [33], it was later approved as a 
potential anticancer drug [34], a specific inhibitor of 
the mammalian target of rapamycin (mTOR) signaling 
pathway, master regulator of cell growth and metabolism 
implicated in a number of diseases including diabetes and 
Figure 9: Quantification of mast cell numbers. Note that the highest numbers of mast cells were obtained in groups 1 and 5. 
Treatment with metformin and rapamycin alone or in combination with probiotics were able to reduce the mast cells number in a significant 
manner. The lowest values were obtained in group 4B and 8B when probiotics were administrated to mice in addition to the metformin 
and rapamycin’s combination. The values represent mean ± SEM (n = 6). Significance of p<0.05 was indicated by (*) when compared to 
diabetic control, and non-diabetic control (**).
Figure 10: Quantification of ROS formation in the different diabetic and non-diabetic groups. Note that the highest ROS 
levels were obtained in the non-treated groups (1 and 5), the different treatments and their combinations were able to reduce ROS levels 
to a various extent in a significant manner. The values represent mean ± SEM (n = 6). Significance of p<0.05 was indicated by (*) when 
compared to diabetic control, and non-diabetic control (**).
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cancer [35]. However, the modest effect of rapamycin-
based therapy has prompted investigators, including our 
laboratory, to consider combination therapy of metformin 
and rapamycin, especially that metformin administration 
significantly reduced CRC incidence [36].
Such in vivo data also supported by in vitro data in 
our laboratory, using either metformin alone, rapamycin 
alone or a combination of the 2 drugs, on decreasing the 
proliferative activity of HCT116 and HT29 colonic cell 
lines, whereby a physiological and supraphysiological 
doses the 2 drugs were not toxic and well tolerated by 
the animals. In this study, despite the fact that rapamycin 
and metformin were used in combination, with or without 
probiotics, they did not lead to unfavorable toxicity, 
as depicted by histological assessment of liver and 
kidney biopsies, while triggering tumor regression, thus 
suggesting their potential value for treatment of CRC in 
diabetes.
As expected, the clinical profile of the controls 
untreated xenografts was the worst. The individual 
treatments helped removing some of the symptoms and 
signs but more so was achieved with the combination 
therapy, in particular, when probiotics were added to 
the combination. Such an effect was more remarkable 
in diabetics versus non-diabetics. Based on clinical 
observations, the highest disease activity (DAI) was 
detected in the non-treated animals to significant extents; 
however, each drug had some positive effect on the DAI, 
more so for metformin than rapamycin. On the other 
hand, there were no significant additive effects between 
metformin and rapamycin except when supplemented 
with probiotics, then all symptoms and signs decreased 
significantly in all diabetics and non-diabetics.
In line with published reports, metformin 
significantly reduced or delayed the occurrence of CRC 
development in the animals; it worked as an independent 
protective factor against CRC [36]. It might have exerted 
its cancer chemo preventive effects by suppressing the 
transformation and hyper proliferative processes that 
initiate carcinogenesis [37]. Similarly, rapamycin has 
also exercised its potential as an anticancer drug in this 
rapamycin-sensitive cancer model, but to a very low 
level, compared to metformin alone or the combination 
plus probiotics. In brief, the 2 drugs showed remarkable 
effects in preventing or slowing down the progress of 
the development of the xenograft. Such an effect was 
consistent in delaying tumorigenesis particularly when 
probiotics were added in G4B (for 3/5) for 14 days and 
in G8B (3/5) for 15 days; p-mTOR has been suppressed 
significantly in both groups.
At the same time, there was a decrease in size 
of the tumor in almost all treated groups, to various 
extents, compared to untreated animals. Again, little 
but significant effects were encountered with each drug 
separately with no indication of added effects except 
when probiotics were in the combination. The probiotics 
treated animals had decreased size and frequency of 
all tumors in both diabetics and to a lesser extent in 
non-diabetics (Figures 7 and 8). Such effects were 
very significantly correlated with improvements in 
pathological alterations in the various groups. Each of the 
2 drugs had moderate effects which did not add, but were 
Figure 11: DHE staining in non–diabetic animals, groups 1, 2, 3, 4A and 4B, as well as in diabetic animals (groups 5, 
6, 7, 8A and 8B) showing the difference in stain intensity when comparing the non-treated group 1 and 5 to the treated 
groups. Note that the lowest red fluorescence was obtained in group 4B and 8B treated with the combination of metformin, rapamycin 
and probiotics.
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conspicuous in terms of smaller size, lower cell density 
and less inflammatory cells leading to less production of 
pro-inflammatory agents IL-3, IL-6 and TNF-α and less 
ROS production.
Concerning the colon, most alterations in colonic 
tissues improved remarkably by treatment with either 
drugs. However, such improvements were more evident 
when combination therapy was adopted in G4A (0.6/3) 
and G8A diabetics (1.0/3), and even more prominent 
when probiotics were added, reaching a histological 
status very close to normal. The inhibition of mast 
cells followed a similar pattern and the panoply of 
inflammatory mediators, secreted by these cells, 
decreased as the number of mast cells decreased to 
various extents in the different groups commensurate 
with decrease in pro-inflammatory mediators and the 
improvement or limitation of the inflammatory reaction 
in the various groups. Again, no signs of added effects 
among the 2 drugs, but the presence of probiotics, one 
more time, did make a positive impact on the tissues 
Figure 12: (A and B) Expression of main genes involved in colorectal carcinogenesis. The values represent mean ± SEM (n = 6). 
Significance of p<0.05 was indicated by (*) and (**) when compared to diabetic control and non-diabetic control respectively.
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and cells of the colon. Were the drugs working by 
different mechanisms, and how did the probiotics make 
the difference? Did they affect ROS production and 
controlled ROS activity?
In general, cancer cells increase their rate of ROS 
production, compared to normal cells, and increase 
their susceptibility to ROS-manipulation therapies. 
The association of ROS with cancer cells could be 
oncogenic at high levels [38] thus promoting cancer 
cell proliferation, survival, angiogenesis and metastasis 
[39]. To maintain redox balance, cancer cells increase 
their antioxidant capacity by scavenging excess ROS. 
Data emanating from this study showed that the 2 drugs 
rapamycin and metformin could decrease significantly 
ROS levels in both diabetics and non-diabetics without 
showing any added value to the combination therapy 
even with probiotics. As expected, the highest values of 
ROS were associated with the non-treated xenografted 
animals with or without diabetes. The mechanism of 
ROS reduction by the 2 drugs is probably independent 
of that of probiotics. This increase in oxidative stress 
induced more cancer cell death and smaller tumors [40]. 
The cancer cells were as sensitive in both metformin and 
rapamycin treated animals. Actually, ROS was probably 
maintained in the various groups at a level that allows 
for the activation of protumorigenic signaling pathways. 
Hence, strategies to eliminate ROS or produce ROS 
may be effective in cancer therapies. In this study, both 
drugs led to a remarkable decrease in ROS production 
and consequently a reduction in its pro-cancer effect. 
ROS could have also oxidized and inactivated MAPK 
phosphatases and MAPK/ERK pro-proliferative 
signaling [41]. They could have also promoted tumor 
cell survival through the activation of NFKB and NRF2 
transcription factors that upregulate the expression of 
antioxidants to evade ROS mediated cancer cell death 
[42].
Moreover, data showed that high values of 
ROS promoted tumor angiogenesis and metastasis 
as detected in G1 and G5 control non-treated groups. 
Such cases are usually associated with poor prognosis 
and activate the AMPK [43]. Actually, ROS levels 
increased in these solid tumors and AMPK was 
activated to probably promote NADPH production. On 
the other hand, loss or significant decrease of AMPK 
by metformin or rapamycin, could have prevented 
oncogenic transformation [44]. In brief, ROS has been 
shown to regulate numerous signaling pathways (e.g. 
MAPK PI3K/Akt and JNK pathways) and decreasing 
ROS levels could prevent cancer cell proliferation. 
Therefore, developing methods to decrease intracellular 
ROS levels and prevent cancer cell proliferation is an 
attractive field. So far, ROS manipulation strategies 
have previously focused on antioxidant therapy. A better 
understanding of the molecular mechanisms of ROS 
signaling in cancer and the identification of specific 
ROS targets may provide novel therapeutic avenues 
for treating cancer. Could probiotics be performing 
this task? Data in this study do not clearly support this 
claim.
On the other hand, emerging research on CRC 
points out to a complex network of genetic alterations 
leading to dysregulation of multiple pathways. Moreover, 
as proposed by CRC subtyping consortium, there are 4 
major molecularly distinguishable subtypes of CRC 
[45] and when coupled with T2DM, they tend to have 
a less favorable prognosis [46]. Further, patients with 
inadequate glycemic control may have an even higher 
risk of CRC and need to receive polytherapy [47]; a 
potential indication for metformin and rapamycin. In this 
context, observational studies have suggested that some 
anti-hyperglycemic agents like metformin, could decrease 
or prevent cancer risk [48] [49] could activate AMPK, a 
central regulator and an important target for controlling 
Figure 13: Assessment of proliferation via KI67. The values represent mean ± SEM (n = 6). Significance of p<0.05 was indicated 
by (*) and (**) when compared to diabetic control and non-diabetic control respectively.
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human diseases including T2DM and cancer. AMPK 
could cause cell cycle arrest in response to metabolic 
stress through a number of mechanisms [50]. In addition, 
AMPK might protect sometimes tumor cells against 
action of cytotoxic agents and hypoxia once tumor is 
established, or even delay the onset of tumorigenesis 
[32]. Along this line, studies on the AMPK have shown 
that mTORC1 and RNA polymerase I transcription 
factor TIF-1A, both of which are required for rapidly 
proliferating cells, are under the control of AMPK [32].
In this study, AMPK levels in non-treated diabetics 
(G5) were 31% lower than in non-treated non-diabetics 
(G1). When metformin was administered alone, a slight 
decrease in AMPK was also observed. Notably, when 
probiotics were added, these levels decreased remarkably 
in diabetics and non-diabetics by 40%. This behavior 
remains unexplained and requires further explanation 
as to decipher the mechanism which lowered AMPK 
despite the administration of metformin, an AMPK 
activator.
Figure 14: (A, B, C) Expression of main genes involved in inflammation. The values represent mean ± SEM (n = 6). Significance 
of p<0.05 was indicated by (*) and (**) when compared to diabetic control and non-diabetic control respectively.
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On the other hand, the mTOR pathway components 
are over expressed in CRC [51]. The mTOR combines 
with raptor( regulatory associated protein of mTOR) 
to constitute mTOR complex 1(mTORC1) and rictor 
(rapamycin-insensitive companion of mTOR) to make 
mTORC2 [52].Consequently, mTOR also emerged 
as a compelling molecular target for treating several 
malignancies [53]. There are two different types of 
mTOR inhibitors, (1) ATP competitive mTOR inhibitors 
that block the activity of mTORC1/mTORC2, and(2) 
rapamycin analogs that influence the activity of mTORC1 
[54]. Which one applies in this study?
Actually, rapamycin inhibits the mTORC1 activity, 
suppresses the proliferation of the adenoma cells, 
inhibits of tumor angiogenesis and decreases the size 
and number of polyps [55]. It also inhibits tumor growth 
in a dose dependent reduction in HCT116 xenografts 
[56]. All such effects are encountered in this study. The 
mTORC gene expression was minimal or not expressed 
at all except in the rapamycin treated diabetic animals 
where it exhibited relatively high values. However, the 
expression at the protein level was relatively highest in 
the rapamycin treated diabetics in concordance to the 
gene expression level. On the other hand, the expression 
of p-mTOR protein was relatively more suppressed in 
the combination therapy especially when probiotics 
were added, both with diabetics and non-diabetics. 
Among the rest of the groups mTOR and p-mTOR 
were moderately expressed. Consequently, the clinical 
improvements of the health status of the animals and of 
the cancers did not seem to be related to the p-mTOR 
levels of suppression.
Data of K167 depicted that the proliferation of the 
cancer cells continued in these suppressed groups but at 
a much lower pace, a phenomenon which might explain 
the decrease in size of the tumors in the suppressed 
groups. Such changes were in concordance with the 
lower levels of gene expression of molecules involved 
in the mTOR pathway. The uncontrolled mTORC1 
mediated signaling could be basically explained by the 
intricate signaling network of mTOR and possibly the 
inability of rapamycin to completely block mTORC1 
mediated signaling events which could be explained 
by the presence of several feedback loops, and the 
upregulation of compensatory pathways that promote 
cell survival and growth.
As for the proinflammatory cytokines, IL-6, 
IL-3 and TNF-α gene expression was remarkably 
suppressed in all groups, to various extents, except 
in the non-diabetic non-treated animals. There was 
obviously no added effect of the 2 drugs except in the 
presence of probiotics. In brief, the drugs did control 
to various extents the inflammatory process. However, 
the inflammatory cytokines which were supposed to 
activate mTOR [57] were suppressed, in particular, when 
using the combination of rapamycin and metformin, 
in presence or absence of probiotics. It seems, in this 
case that the treatment with rapamycin might be further 
potentiated with the antidiabetic drug metformin 
[58, 59] and even more so by probiotics. Such results 
Figure 15: Expression of mTOR and p-mTOR at protein level in the different groups. The values represent mean ± SEM (n 
= 6). Significance of p<0.05 was indicated by (*) and (†) when compared to diabetic control, (**) and (‡) when compared with non-diabetic 
control (**) for mTOR and p-mTOR respectively.
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were more evident when the p-mTOR protein was 
assessed; it depicted a much lower expression than 
the mTOR especially with metformin, rapamycin, and 
the 2 drugs in presence of probiotics, both in diabetic 
and non-diabetic animals. The additive effect of both 
drugs was not significant. Such results are congruent 
with the other data collected on proliferation, ROS 
production, mast cells decrease, inhibition of colonic 
inflammation, improvement of histological alterations, 
lower DAI severity and, to some extent, with the 
decrease in tumor volume in both diabetics and non-
diabetics. The presence of probiotics in the combination 
of metformin and rapamycin led through one or more 
mechanisms, to the suppression of tumor size, delay 
in their development, significant inhibition of the 
inflammatory reaction, as well as a decrease in ROS 
production, lower cell proliferation, significant decrease 
in AMPK and inhibition of the phosphorylated mTOR. 
Further experiments are needed in this area to elucidate 
the complexity of the pathways involved and eventually 
the specific targeted molecules as well as the exact role 
of probiotics and their mechanism of action.
The emergence of combination therapy with 
rapamycin and metformin and/or probiotics may further 
increase efficacy and bypass possible feedback activation 
of survival pathways. Significant promise remains for the 
discovery of new specific signaling inhibitors to reduce 
mTORC activation, in monotherapy or in polytherapy and 
decipher the place and role of probiotics in this complex 
process (Figure 16).
The findings reported in this article suggest that 
modulation of the gut microbiome with probiotics in 
combination with the anti-proliferative agents, i.e. 
rapamycin and the antidiabetic drug metformin, a 
potential prebiotic agent, could constitute or be a part 
of a new preventive and or therapeutic strategy for CRC 
management, one of the most common cancers worldwide.
In conclusion, the synergetic action of rapamycin 
and metformin in association with the probiotics led 
to reduced expression of early lesions in CRC such 
as aberrant crypt foci (ACF). Supplementation of the 
combination by probiotics for two weeks, in mice with 
xenografts could possibly lead to a decrease in the 
formation of classical ACF, an increase in apoptosis and 
reduced rates of inflammation, PCNA and p 53 positive 
cells.
It is likely that the established chronic 
inflammatory process combined with dysbiosis 
could contribute to an oxidative stress, an increase 
in reactive oxygen and nitrogen species, as well as 
pro-inflammatory cytokines; key factors involved in 
the development of CRC. Such factors were reduced 
by the various treatments to different extents. To 
reduce or inhibit carcinogenesis linked to oxidative 
stress, a strategy of chemo prevention involving 
the administration of exogenous compounds which 
intervene with the proliferation of cancer cells and with 
the blocking of their oncogenic transformation, as well 
as lowering hyperglycemia, could probably constitute a 
novel strategy. Would metformin and rapamycin coupled 
with probiotics serve the purpose?
Figure 16: Proposed mechanism of action of the tri-therapy.
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MATERIALS AND METHODS
Animals
Fifty male NOD/SCIDs mice 6-8 weeks old, 
weighing 25–30 g, were housed in Individually Ventilated 
Cages ( IVC) at the transgenic unit of the Animal Care 
Facility of the American University of Beirut, in a 
controlled temperature (21°C±2°C) and humidity, with an 
alternating 12-hour light/dark cycle. Standard Laboratory 
pellet formula and tap water were provided ad libitum. 
All animal treatments adhered strictly to institutional 
and international ethical guidelines of the care and use 
of laboratory animals. The experimental protocol was 
approved by the Institutional Animal Care and Use 
Committee, American University of Beirut, Lebanon 
(identification number # F16-00328).
Experimental design
The animals were divided into 2 main groups, (1) 
diabetic and (2) non-diabetic. They were all subject to one 
subcutaneous injection of 3×106 HCT116 cells suspended 
in 200 μl normal physiological saline, in the flank which 
produced xenograft tumors after 9 days.
Diabetes was induced using Streptozotocin (STZ) 
(S0130-50MG-Sigma Aldrich), a N-nitroso-containing 
compound that acts as a nitric oxide donor in the pancreatic 
islets of Langerhans; induces death of insulin-secreting 
cells, and thus producing an animal model of diabetes. 
Two Streptozotocin intra-peritoneal injections at day 1 
and 8 were able to induce diabetes (glycemia >150 mg/dl).
For metformin (Glucophage) treatment, it was 
dissolved in drinking water to attain the dosage of 150 
mg/kg body weight. The water was changed daily and 
measured for water intake. Metformin daily treatment was 
initiated 7 days before inoculation of the tumor cells and 
was continued until sacrifice.
As for rapamycin, (37094-10MG-Sigma Aldrich), it 
was stored at -20° C; diluted with DMSO and administered 
via 100 μl i.p injections (3 injections per week) at a 
dose of 0.5 mg/kg. The first injection of rapamycin was 
administered to the respective groups, 1 week after the 
onset of tumors, i.e. when tumor size reached 50mm3.
Probiotics (Probiolife®), a symbiotic mixture, 
combining the most studied strains of probiotics such 
as lactobacillus rhamnosus, Saccharomyces boulardii, 
Bifidobacterium breve, bifidobacterium lactis, 
lactobacillus acidophilus, lactobacillus plantarum, 
lactobacillus reuteri, in addition to prebiotics and zinc, 
were administered to mice in their drinking water 2 weeks 
before sacrifice. One capsule was dissolved in 1.75 L of 
autoclaved tap water with a concentration of 108 CFU/ml. 
Fresh solution was given to the animals every 2 days.
Each of the 2 main groups of 25 mice was subdivided 
into two subgroups, 15 mice treated with metformin, 150 
mg/kg body weight administered in drinking water, and 
10 mice not treated. A total of 10 groups of 5 animals 
each were reached: group 1 received no treatment and 
was considered as control; group 2 received rapamycin 
only; group 3 was treated with metformin alone; group 
4A was treated with both metformin and rapamycin; and 
group 4B received probiotics in addition to metformin 
and rapamycin. On the other hand, the diabetic mice, 
treated with STZ were divided similarly: group 5 received 
nothing; group 6 rapamycin; group 7 metformin; group 8A 
metformin and rapamycin; and lastly group 8B received 
probiotics in addition to metformin and rapamycin.
Monitoring
Mice were monitored for glycemia pre and post 
STZ injections and weekly afterwards. Weight changes 
(weight loss), stool aspect (loose or bloody), fur shape and 
activity were daily checked. In order to determine tumor 
volume, the maximal longitudinal (length) and transverse 
diameters (width) were measured using a caliper square, 
once per week. Tumor volumes were calculated using 
the formula: tumor volume=length×width×width/2. The 
scores were recorded to calculate disease activity index 
(DAI) based on a previously published scale of zero to 4 
for any parameter; normal status should remain as zero 
and highest activity as 9 [60, 61].
Sacrifice
Dissection and tumor excision were done when 
tumor size reached 1cm3. The animals were anesthetized 
by an overdose of Forane (Isoflurane), the abdominal 
cavity was exposed and a macroscopic assessment of 
the inflammatory status was performed according to an 
already published scale [60].
Biopsies of the descending colon (DC), small 
intestine, liver and kidneys were collected. The tissues 
obtained were either transferred into labeled aliquots, 
snap-frozen in liquid nitrogen, and kept at -80°C 
for further molecular analysis or were kept in 10% 
formaldehyde to be processed with paraffin for routine 
light microscopy and histology analysis according to 
previously reported procedures [60].
Real time RT-PCR
The total RNA of the tissues was extracted using an 
RNeasy mini-kit (Qiagen Ltd., Crawley, United Kingdom). 
RNA quantity and purity were assessed using NanoDrop 
ND-1000 spectrophotometer (Wilmington, NC). M-MLV 
Reverse Transcriptase buffer pack (Promega, Lyon, 
France) was used for reverse transcription. Primers were 
designed for the determination of the following gene 
expression: mTORC1, AMPK, IL-6, IL-3, and TNF-ɑ. 
GAPDH was used as an internal control. The amplification 
was monitored with StepOnePlus PCR System (AB 
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Applied Biosystems, Villebon-sur-Yvette, France) using 
GoTaq qPCR Master Mix (Promega, Charbonnieres Les 
Bains, France) according to manufacturer's instructions. 
Samples were run in triplicate, relative abundance of 
each target was normalized to GAPDH expression and 
gene regulation was determined by the quantitation-
comparative ΔΔCT method [62].
Western blot
Protein extraction and quantification were 
performed using previously established protocols. The 
extracted proteins were separated by gel electrophoresis 
and were transferred onto nitrocellulose membranes. 
The membranes were blocked with 5% bovine serum 
albumin in Tris-buffered saline and probed with 
primary antibodies specific for phospho-mTOR, and 
mTOR (all from Cell Signaling Technology) and 
GAPDH. Horseradish peroxidase-conjugated secondary 
antibodies and the ECL detection kit (Bio-Rad) were 
used for the detection of specific proteins. Bands were 
quantified and normalized to the signal generated from 
GAPDH.
ROS detection by DHE staining
Frozen sections, from frozen tissue stored at 
(-80), were prepared. The tissue was demarcated with 
a solvent resistant pen. DHE solution was prepared and 
dispensed over the tissue and the slides placed for 30 min 
at 37°C. Then the DHE residues were removed, slides 
counterstained with DAPI, colversliped and stored at 
4°C (light sensitive) until microscopic evaluation and 
quantification using Zen software. One way ANOVA: to 
compare between all of the groups and T-test: to compare 
between two groups were done [60].
Histology
Tissue preparation for light microscopy was 
performed according to routine procedures and 
protocols already established in the laboratory [60]. The 
histological alterations were assessed using a previously 
published scale illustrated in Table 2 [60]. Fields at 200 x 
magnification were photographed, evaluated and scored by 
2 independent researchers. The scores of two independent 
observers were averaged. The histological grades (from 
“0 to 21”) indicating the numerical sum of scoring criteria 
were divided by 7 (the number of criteria), averaged to 
obtain a maximum average of 3, computed and represented 
with matching standard error of the mean [60].
Mast cells count
The evaluation of mast cell count was performed by 
two different observers according to previously reported 
criteria on slides stained with Toluidine Blue (TB) [60].
Statistical analysis
Statistics were conducted using the analysis of 
t-test and ANOVA to compare each experimental group 
to the corresponding controls using the STAT3 software. 
Significance was determined as probability (p) <0.05.
Table 2: Criteria for microscopic grading of experimental chronic colitis [60]
Histologic grading
Feature 0 1 2 3
Abnormalities of 
mucosal architecture None (Normal)
Mild or focal, not 
exceeding lamina 
propria
Moderate, not 
exceeding the 
submucosa
Severe & diffuse, 
exceeding the 
submucosa
Crypt abnormalities None Mild atrophy Moderate atrophy, Branched crypts
Severe atrophy, 
branched crypts, 
cryptitis, crypt abscess
Inflammatory cell 
infiltration Normal Scattered cells
Moderate or confluent 
cells
Massive infiltration of 
cells
Vascular dilatation Normal Mild dilatation (localized)
Moderate dilatation of 
several blood vessels
Severe generalized 
dilatation of blood 
vessels
Edema None Low level limited to villi In the submucosa All over the section
Mast cells Normal Three cells clustered in submucosa
Clusters of > 3 cells in 
the submucosa
Clusters in submucosa 
and serosa
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Limitations of the study
This study has several limitations. First, a small 
number of animals per treatment group was used (n=6), 
especially in the probiotics treated mice, whereby, more 
controls groups could have been also included. Moreover, 
this study only assessed the response of male NOD/SCIDs 
mice, it would have been better if the 2 genders were part 
of the study.
Another major limitation of this CRC model is the 
NOD/SCIDs mice, they have a compromised immune 
system leading to the loss of the complex interactions 
between tumor and host. Thus, they may not represent the 
behavior of naturally occurring cancers in humans.
Another restraint is the genetic and epigenetic 
changes which may occur in the tumor cells during culture 
and implantation, despite the fact that the cells were in 
early stages of culture.
Therefore, future studies assessing the effects of 
rapamycin, metformin and probiotics should be conducted 
on a larger number of animals from both genders. Clinical 
studies are also required to demonstrate the beneficial 
effects of these treatments on patients and to elucidate 
the safety and correct regimens for the prevention and 
management of CRC.
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